Skip to content
Clinical Trials – home

Hospital Universitario Fundacion Jimenez Diaz

Verified siteinfo

Spain Avenida De Los Reyes Catolicos 2, 28040 Madrid, Spain

  • 218 trials recruiting
  • Non-small cell lung cancer · Neoplasm · Neoplasm malignant
  • Adults and children

About Specializations

Hospital Universitario Fundacion Jimenez Diaz in Madrid, Spain specialises in clinical trials of conditions such as Non-small cell lung cancer, Neoplasm, Neoplasm malignant, Non-small cell lung cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Hematologic Malignancies

At Hospital Universitario Fundacion Jimenez Diaz in Madrid, a major share of research focuses on neoplasms and blood cancers, with studies spanning non-small cell lung cancer, breast cancer, ovarian cancer, lymphoma, and multiple myeloma. These trials are largely designed to test new cancer treatments, combine therapies in smarter ways, and improve outcomes for patients with advanced or treatment-resistant disease.

  • Solid tumors including lung, breast, ovarian, colorectal, pancreatic, hepatobiliary, and gastrointestinal cancers
  • Lymphomas and other hematologic malignancies such as diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma
  • Research aimed at evaluating immunotherapy, targeted treatment strategies, and treatment effectiveness in advanced cancer

The oncology portfolio is broad and highly active, reflecting the site’s strong role in studies of both common and rare cancers, with a clear emphasis on finding better options for people whose disease has progressed after standard care.

Cardiovascular and Renal Research

Cardiovascular studies at this site address conditions such as heart failure, acute myocardial infarction, and inherited risk for dilated cardiomyopathy, while renal research includes chronic kidney disease and focal segmental glomerulosclerosis. The main purpose is to improve prevention, protect organ function, and evaluate whether new approaches can reduce complications after major cardiac events or surgery.

  • Heart failure, acute decompensated heart failure, and post-infarction recovery
  • Genetic cardiomyopathy and strategies to prevent early disease progression
  • Kidney disease research focused on preserving renal function and reducing surgery-related injury

These studies combine disease prevention and treatment optimization, showing a strong interest in earlier intervention and better long-term outcomes for patients with cardiovascular and kidney disorders.

Neurology, Sleep, and Seizure Disorders

Research in nervous system diseases includes trials for epilepsy, focal onset seizures, chronic migraine, and glioblastoma, along with studies exploring sleep-related symptoms such as insomnia. The goal is to assess new therapies that may better control symptoms, reduce seizure burden, and improve daily functioning.

  • Epilepsy and focal seizures in adults and younger patients
  • Insomnia and sleep disturbance linked with other health conditions
  • Brain tumor research, especially glioblastoma, focused on improving treatment response

This area reflects a practical clinical focus on conditions that can strongly affect quality of life, with trials seeking safer and more effective ways to manage persistent neurological symptoms.

Digestive, Liver, and Inflammatory Disease Studies

The site also conducts research in digestive system diseases and immune-related conditions, including Crohn's disease, complex perianal fistulas, hepatocellular carcinoma, cholangiocarcinoma, and other gastrointestinal cancers. These studies aim to improve treatment options, support healing in inflammatory bowel disease, and evaluate new approaches for hard-to-treat liver and gastrointestinal malignancies.

  • Crohn's disease and associated fistulizing complications
  • Hepatobiliary cancers such as hepatocellular carcinoma and cholangiocarcinoma
  • Gastrointestinal cancers including gastroesophageal and colon malignancies

These trials highlight a mix of regenerative, surgical, and drug-based research, all aimed at improving control of chronic inflammation and difficult digestive cancers.

Ophthalmology, Infectious Disease, and Immune-Mediated Conditions

Additional research at Hospital Universitario Fundacion Jimenez Diaz covers eye diseases, virus diseases, and immune system diseases, including geographic atrophy, uveitic macular edema, HIV-1 infection, RSV-associated disease, and monkeypox. The main aim is to improve diagnosis, preserve vision, and test better preventive or treatment options for infectious and immune-driven conditions.

  • Retinal and inflammatory eye disease, especially geographic atrophy and uveitic macular edema
  • HIV-1 treatment and treatment-switch studies
  • Viral infections and vaccine-related research for emerging and respiratory pathogens

This portfolio shows the site’s wide clinical reach, extending beyond oncology and cardiology into vision care, infectious disease, and immune-mediated disorders where better long-term control is needed.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida De Los Reyes Catolicos 228040 MadridSpain
Recruiting now
218 trials
Conditions studied
313
Partner status
Verified site

More sites in MadridSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

621 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Study of lunsekimig versus placebo in adults with inadequately controlled eosinophilic COPD

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study to evaluate the safety and effectiveness of HLX43 in patients with advanced non-small cell lung cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:HLX43
  • Sponsor:Shanghai Henlius Biotech Inc.

Breast cancer

Recruiting

Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimeticone
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.